Clinical trial · Interventional
Wholebody MRI In Lung Cancer StagiNg
Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in detection of nodes in patients with cell lung cancer (NSCLC). However, the cardiorespiratory synchronization in the MRI, allowing acquisition of synchronous images with breathing and heart movements should increase the sensitivity of detection of pathologic mediastinal lymph nodes. Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as informative as PET, while being less expensive, not radiant. The purpose of this study is to evaluate the performance of whole-body MRI with diffusion with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are known to be less well detected by MRI) compared to PET.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Device | — | UNRESOLVED |
| PET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MRI
- description
- Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
- interventionNames
- Device: MRI
- type
- ACTIVE_COMPARATOR
- label
- PET
- description
- At day 1 , in the morning, patient will undergo an PET analysis
- interventionNames
- Device: PET
Primary outcomes (1)
- measure
- Th consistency of the locations of mediastinal lesions
- timeFrame
- Day 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years, * Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed, * Patient potentially eligible for curative treatment, but no no treatment started, * Patients for whom a PET scan and MRI are planned Non Inclusion Criteria: * claustrophobia, * Implantable Medical Device * not compatible pacemaker type or heart valve, metal splinters eye) * Pregnant or lactating women,
References
Publications (0)
Data not yet available